Literature DB >> 19219075

Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?

M Breccia, L Cannella, C Stefanizzi, A Carotti, M Santopietro, G Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19219075     DOI： 10.1038/bmt.2009.20

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

1.  Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

2.  Development of severe sclerotic chronic GVHD during treatment with dasatinib.

Authors:  D Pulanic; E W Cowen; K Baird; M R Bishop; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

3.  Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy.

Authors:  Mariana Serpa; Sabri S Sanabani; Israel Bendit; Fernanda Seguro; Flávia Xavier; Cláudia Bitti Barroso; Monika Conchon; Pedro Enrique Dorlhiac-Llacer
Journal:  Clin Med Insights Oncol       Date:  2010-12-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.